The Microbiome: From decoding nature to biotech breakthroughs

The Microbiome: From decoding nature to biotech breakthroughs

Thursday, October 1, 2020 5:00 PM to 5:45 PM · 45 min. (Africa/Abidjan)
Breakout Session
October 1

Information

Interest in the human microbiome—the ≈2 kilos and trillions of diverse bacteria that inhabit the large intestine—isn’t just hype or a natural healing trend. A significant uptick in basic science is studying the complex relationship between the microbiome, hormones, nervous and immune system, and beyond. While we turn insights into action, will interest in microbiome health fade or accelerate? We’ll look at the latest in microbiome research, explore our complex relationships with natural versus engineered treatments, and how the two might co-exist.

Leaps by BayerLeaps by Bayer is the impact investment unit of Bayer AG.  Leaps invests in paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better.  Leaps by Bayer aims to conquer ten huge challenges facing humanity. Some people call them impossible. We call them “leaps.” Much of what we are aiming to achieve is not yet possible. Setbacks and failures are to be expected in dealing with such ambitious targets. Our approach is making significant and sustained investments in disruptive biotechnologies that could have the greatest impact on humanity.

Registered attendees

Alex Rosay
Alex Rosay
Product ManagerZymergen
AC
Anupam Chowdhury
Bioinformatics ScientistZymergen
Beth Bannerman
Beth Bannerman
SVP, Corporate Communications5885 Hollis Street Suite 100